BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12469933)

  • 1. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
    Dutcher J
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pathways for managing patients receiving interleukin 2.
    Mavroukakis SA; Muehlbauer PM; White RL; Schwartzentruber DJ
    Clin J Oncol Nurs; 2001; 5(5):207-17. PubMed ID: 11905416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
    Dutcher JP
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):4-10. PubMed ID: 12469934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
    Dutcher JP
    Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
    [No Abstract]   [Full Text] [Related]  

  • 5. CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype.
    Beyer M; Schultze JL
    J Clin Oncol; 2007 Jun; 25(18):2628-30; author reply 2630-2. PubMed ID: 17577047
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
    J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2.
    O'Reilly F; Feldman E; Yang J; Hwu P; Turner ML
    J Am Acad Dermatol; 2003 Apr; 48(4):602-4. PubMed ID: 12664026
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal-cell carcinoma.
    Vincenzi B; Santini D; Tonini G
    N Engl J Med; 2006 Mar; 354(10):1095-6; author reply 1095-6. PubMed ID: 16528812
    [No Abstract]   [Full Text] [Related]  

  • 9. [Regional immunotherapy of metastatic renal cell carcinoma].
    Heinzer H; Huland E; Huland H
    Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer.
    Logan TF; Bensadoun ES
    Thorax; 2005 Jul; 60(7):610-1. PubMed ID: 15994271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotherapy skin reaction.
    Newton S; Jackowski C; Marrs J
    Clin J Oncol Nurs; 2002; 6(3):181-2. PubMed ID: 11998617
    [No Abstract]   [Full Text] [Related]  

  • 12. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
    McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
    Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2.
    Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
    [No Abstract]   [Full Text] [Related]  

  • 14. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
    Kirkwood JM; Tarhini AA
    J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis.
    Brusky JP; Gailani F; Pathak A; Patel H; Aboseif S
    BJU Int; 2006 Feb; 97(2):279-80. PubMed ID: 16430629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
    Hashmi MH; Van Veldhuizen PJ
    Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
    Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
    Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
    Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
    Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
    Khong B; Lawson BO; Ma J; McGovern C; Van Atta JK; Ray A; Khong HT
    BMC Cancer; 2018 Oct; 18(1):1007. PubMed ID: 30342473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.